170 related articles for article (PubMed ID: 30652947)
21. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate.
Palmer RB
Toxicol Rev; 2004; 23(1):21-31. PubMed ID: 15298490
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome.
Kamal RM; Dijkstra BA; Loonen AJ; De Jong CA
J Addict Med; 2016; 10(4):229-35. PubMed ID: 27310146
[TBL] [Abstract][Full Text] [Related]
23. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
[TBL] [Abstract][Full Text] [Related]
24. Sociodemographic and substance use characteristics of γ hydroxybutyrate (GHB) dependent inpatients and associations with dependence severity.
Brunt TM; Koeter MW; Hertoghs N; van Noorden MS; van den Brink W
Drug Alcohol Depend; 2013 Aug; 131(3):316-9. PubMed ID: 23332440
[TBL] [Abstract][Full Text] [Related]
25. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
[TBL] [Abstract][Full Text] [Related]
26. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
[TBL] [Abstract][Full Text] [Related]
27. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management.
Rosenberg MH; Deerfield LJ; Baruch EM
Am J Drug Alcohol Abuse; 2003 May; 29(2):487-96. PubMed ID: 12765217
[TBL] [Abstract][Full Text] [Related]
28. [Gamma-hydroxybutyrate--an endogenous substance and an intoxicant].
Hovda KE; Liberg JP; Nordby G; Jacobsen D
Tidsskr Nor Laegeforen; 1998 Nov; 118(28):4390-3. PubMed ID: 9889613
[TBL] [Abstract][Full Text] [Related]
29. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal.
Bowles TM; Sommi RW; Amiri M
Pharmacotherapy; 2001 Feb; 21(2):254-7. PubMed ID: 11213862
[TBL] [Abstract][Full Text] [Related]
30. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
Wojtowicz JM; Yarema MC; Wax PM
CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
[TBL] [Abstract][Full Text] [Related]
31. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal.
Miotto K; Darakjian J; Basch J; Murray S; Zogg J; Rawson R
Am J Addict; 2001; 10(3):232-41. PubMed ID: 11579621
[TBL] [Abstract][Full Text] [Related]
32. [GHB withdrawal delirium].
Stijnenbosch PJ; Zuketto C; Beijaert PJ; Maat A
Ned Tijdschr Geneeskd; 2010; 154():A1086. PubMed ID: 20132572
[TBL] [Abstract][Full Text] [Related]
33. [Life threatening symptoms of withdrawal of gamma-hydroxybutyrate].
Veerman SR; Dijkstra HN; Liefting-Kluft I
Tijdschr Psychiatr; 2010; 52(6):411-6. PubMed ID: 20544599
[TBL] [Abstract][Full Text] [Related]
34. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam.
Nava F; Premi S; Manzato E; Campagnola W; Lucchini A; Gessa GL
Am J Drug Alcohol Abuse; 2007; 33(3):379-92. PubMed ID: 17613965
[TBL] [Abstract][Full Text] [Related]
35. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
Leone MA; Vigna-Taglianti F; Avanzi G; Brambilla R; Faggiano F
Cochrane Database Syst Rev; 2010 Feb; (2):CD006266. PubMed ID: 20166080
[TBL] [Abstract][Full Text] [Related]
36. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project.
Dijkstra BA; Kamal R; van Noorden MS; de Haan H; Loonen AJ; De Jong CA
Drug Alcohol Depend; 2017 Jan; 170():164-173. PubMed ID: 27923198
[TBL] [Abstract][Full Text] [Related]
37. Gamma hydroxy butyrate abuse and dependency.
Gonzalez A; Nutt DJ
J Psychopharmacol; 2005 Mar; 19(2):195-204. PubMed ID: 15871147
[TBL] [Abstract][Full Text] [Related]
38. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
[TBL] [Abstract][Full Text] [Related]
39. Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence.
Mannucci C; Pichini S; Spagnolo EV; Calapai F; Gangemi S; Navarra M; Calapai G
Curr Drug Metab; 2018; 19(13):1056-1064. PubMed ID: 29219048
[TBL] [Abstract][Full Text] [Related]
40. Predictors of Leaving an Inpatient Medical Withdrawal Service Against Medical Advice: A Retrospective Analysis.
Ling S; Cleverley K; Brennenstuhl S; Bindseil K
J Addict Med; 2018; 12(6):453-458. PubMed ID: 29939875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
